Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up – Time to Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) gapped up before the market opened on Monday . The stock had previously closed at $4.71, but opened at $4.98. Recursion Pharmaceuticals shares last traded at $4.7250, with a volume of 11,392,895 shares.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on RXRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Trading Down 1.0%

The stock has a market cap of $2.48 billion, a P/E ratio of -2.65 and a beta of 0.94. The firm’s 50 day simple moving average is $5.12 and its two-hundred day simple moving average is $5.14. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The business had revenue of $5.18 million during the quarter, compared to analyst estimates of $19.36 million. During the same period in the previous year, the business posted ($0.34) EPS. The company’s quarterly revenue was down 80.1% on a year-over-year basis. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $4.37, for a total value of $961,400.00. Following the completion of the transaction, the director directly owned 6,869,863 shares in the company, valued at $30,021,301.31. The trade was a 3.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 8.43% of the stock is owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in RXRX. TD Waterhouse Canada Inc. boosted its position in Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the period. AlphaQuest LLC bought a new stake in Recursion Pharmaceuticals in the first quarter valued at $36,000. Caitong International Asset Management Co. Ltd lifted its stake in Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after buying an additional 4,446 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the period. Finally, Janney Montgomery Scott LLC bought a new position in shares of Recursion Pharmaceuticals during the second quarter worth about $51,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.